AstraZeneca CEO Raises Bar for Deals After Acquisitions SpreeBy
`We have what we need to have,' Soriot tells journalists
Any purchase would need to be immediately accretive, CEO says
AstraZeneca Plc pledged to only pursue acquisitions that immediately add to the drugmaker’s bottom line, following a deal spree in the last quarter of 2015.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.